Table 3 Treatment characteristics prior to inclusion in the study, 6 months prior to IAI switch, and 6 months after IAI switch
From: Effect of intravitreal aflibercept on recalcitrant diabetic macular edema
# | Prior to inclusion in study | 6 months prior to IAI switch | 6 months after IAI switch | |||
|---|---|---|---|---|---|---|
Duration treatment (mo) | Total # treatment | Type of treatment | Total # treatment | Type of treatment | Total # IAI | |
l | 60 | 26 | 6 IVB, 16 IVR, 2 IVTA, 1 STTA, 1 laser | 5 | 5 IVR | 4 |
2 | 18 | 10 | 4 IVB, 4 IVR, 1 IVTA, 1 laser | 5 | 3 IVR, 1 IVTA, 1 laser | 6 |
3 | 8 | 5 | 2 IVB, 3 IVR | 4 | 1 IVB, 3 IVR | 5 |
4 | 35 | 30 | 29 IVB, 1 laser | 5 | 4 IVB, 1 laser | 4 |
5 | 43 | 16 | 7 IVB, 8 IVR, 1 IVTA | 5 | 5 IVR | 6 |
6 | 9 | 5 | 4 IVR, 1 laser | 5 | 4 IVR, 1 laser | 4 |
7 | 19 | 16 | 16 IVR | 5 | 5 IVR | 5 |
B | 36 | 18 | 6 IVB, 7 IVR, 2 IVTA, 1 dexamethasone intravitreal implant, 2 laser | 6 | 6 IVR | 4 |
9 | 10 | 6 | 4 IVR, 1 IVTA, 1 laser | 4 | 3 IVR, 1 laser | 5 |
10 | 77 | 7 | 5 IVR, 2 laser | 4 | 4 IVR | 4 |
11 | 33 | 6 | 5 IVB, 1 laser | 4 | 4 IVB | 5 |
Mean = 32 | Mean = 13 | Mean # anti-VEGF = 11.5 | Mean = 4.7 | Mean # anti-VEGF = 4.3 | Mean = 4.7 | |